We are proud to announce that PhenoPath is now a Quest Diagnostics Company.
Bladder cancer is the fourth most common cancer in the United States. Ninety percent of bladder cancers are classified as Transitional Cell Carcinoma (TCC), which are further categorized into 4 clinically relevant subgroups at pathologic staging. While clinical outcome differs for each subgroup, 3 of the 4 groups are “superficial” at presentation but have a high probability (50-80%) of recurrence, and may progress to invasive tumors. Patients with these superficial bladder cancers are regularly monitored for recurrence and progression, typically with cystoscopy and urine cytology. Both of these methods have shown low sensitivity for detecting bladder cancer; newer studies, however, have shown that FISH analysis for aneuploidy of specific chromosomes may be a useful adjunct in detecting bladder cancer
CPT Code(s): 88121. The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.
Turnaround Time: Within 4-6 business days of receipt
Schedule: Monday - Friday
20 mL urine in 10 mL PhenoPath-provided Carbowax fixative (in 50 mL tube) OR at least 20 mL urine Ship immediately on ice. If shipment is delayed, store in refrigerator and ship within 24 hours